A Study of JNJ-95566692 in Participants With Non-Hodgkin Lymphoid Malignancies

The purpose of this study is to determine the putative recommended Phase 2 doses (RP2Ds) and optimal dose schedule(s) for JNJ-95566692 as a single agent (Arm A) and in combination with JNJ-87801493 (Arm B) and for JNJ-95566692 with or without JNJ-87801493 with various standard of care (SOC) regimens (Arms C-G) in Part 1: Dose Escalation part of the study. Part 2: Dose Expansion part of the study will further characterize the safety.

Trial Details

NCT ID
NCT07308132
Phase
PHASE1
Sponsor
Janssen Research & Development, LLC
Status
RECRUITING
Cancer Type
Lymphoma
Interventions
  • JNJ-95566692
  • JNJ-87801493
  • loncastuximab tesirine
  • Lenalidomide
  • Rituximab
  • Gemcitabine
Locations (sample)
  • Clayton, Australia|-37.91667,145.11667
  • Melbourne, Australia|-37.814,144.96332
  • North Ryde, Australia|-33.79677,151.12436
  • Randwick, Australia|-33.91439,151.24895
  • Edegem, Belgium|51.15662,4.44504

Key Eligibility Criteria

  • B-cell non-Hodgkin lymphoid malignancies (NHL) according to World Health Organization (WHO) 2022 and no other approved therapies available that wou…
  • Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1
  • Participants must have measurable disease as defined by the disease criteria (Lugano criteria)
  • While on study treatment and for 3 months after the last dose of study treatment, a participant must: not breastfeed or become pregnant; not donate…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lymphoma Trials on Trialify →